Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-10-10
2006-10-10
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S190100, C424S184100, C530S350000, C530S825000, C514S002600
Reexamination Certificate
active
07118756
ABSTRACT:
The present invention discloses amino acid sequences and nucleic acid sequences relating to aStreptococcus Pneumoniaesurface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa). The PPP exhibits the ability to reduce colonization of pneumococcal bacteria. Thus the present invention also pertains to compositions for the treatment and prophylaxis of infection or inflammation associated with bacterial infection.
REFERENCES:
patent: 4425330 (1984-01-01), Norcross et al.
patent: 5266477 (1993-11-01), Howard et al.
patent: 6291654 (2001-09-01), Hostetter et al.
patent: 6699703 (2004-03-01), Doucette-Stamm et al.
patent: WO 98/18931 (1998-05-01), None
patent: WO 99/15675 (1999-04-01), None
Harlow et al. In: Antibodies: A laboratory Manual. Cold Sprting Harbor Laboratory, Chapter 5, p. 76, 1988.
Houghton et al. Vaccines86, Cold Spring Harbor Laboratory, p. 21-25, 1986.
Conte, et al., “Iron Availability Affects Entry of Listeria monocytogenes into the Enterocytelike Cell Line Caco-2,” Infection and Immunity, Sep. 1996, p. 3925-3929.
Gray-Owen, et al., “Identification and Characterization of Genes Encoding the Human Transferrin-Binding Proteins fromHaemophilus influenzae,” Infection and Immunity, Apr. 1995, p. 1201-1210.
Luke, et al., “Use of an Isogenic Mutant Constructed inMoraxella catarrhalisTo Identify a Protective Epitope of Outer Membrane Protein B1 Defined by Monoclonal Antibody 11C6,” Infection and Immunity, Feb. 1999, p. 681-687.
Pettersson, et al., “Molecular Characterization of the 98-Kilodalton Iron-Regulated Outer Membrane Protein of Neisseria meningitidis,” Infection and Immunity, Nov. 1993, p. 4724-4733.
Pikis, et al., “A Conservative Amino Acid Mutation in the Chromosome-Encoded Dihydrofolate Reductase Confers Trimethoprim Resistance inStreptococcus pneumoniae,” The Journal of Infectious Diseases, 1998; 178:700-6.
Morrison, et al., “Isolation and Characterization of Three New Classes of Transformation-Deficient Mutants ofStreptococcus pneumoniaeThat Are Defective in DNA Transport and Genetic Recombination,” Journal of Bacteriology, Oct. 1983, p. 281-290.
Henriksen, et al., “Vaccination with Protein-Conjugated and Native Type 3 Capsular Polysaccharide in and Ethanol-Fed Rat Model of Pneumococcal Pneumonia,” Alcohol Clin. Exp. Res., vol. 21, No. 9, 1997; p. 1630-1637.
Gray, “Opsonophagocidal Activity in Sera From Infants and Children Immunized With Haemophilus influenzae Type b Conjugate Vaccine (Meningococcal Protein Conjugate),” Pediatrics Conjugate Vaccines Supplement, 1990, p. 694-697.
H. Tettelin, “Complete Genome Sequence of a Virulent Isolate ofStreptococcus pneumoniae” Science, Jul. 2001, vol. 293, 498-506.
Green Bruce A.
Masi Amy W.
Brazil Bill T.
Devi S.
Rozek Carol E.
Wyeth
LandOfFree
Recombinant protective protein from Streptococcus pneumoniae does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant protective protein from Streptococcus pneumoniae, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant protective protein from Streptococcus pneumoniae will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3640038